Key References

• Siltuximab for multicentric Castleman’s disease: a randomised, double-blind, placebo-controlled trial.
  Van Rhee F, Wong RS, Munshi N, Rossi JF, Ke XY, Fossa A, et al.
  Lancet Oncol. 2014;15(9):966-74.
  
  
  

• International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic
  multicentric Castleman disease.
  Fajgenbaum DC, Uldrick TS, Bagg A, Frank D, Wu D, Srkalovic G, et al.
  Blood. 2017;129(12):1646-57.

  
  
  

• International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease.
  Van Rhee F, Voorhees R, Dispenzieri A, Fosså A, Srkalovic G, Ide M, et al.
  Blood. 2018;132(15): 2115-24.

  
  

• Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab.
  Van Rhee F, Rossi JF, Simpson D, et al.
  British Journal of Haematology. 2020 Oct. DOI: 10.1111/bjh.17177.

  
  
  
  

For clinical paper requests, please contact EUSA Medical Information

To find out more about EUSA Pharma privacy practices view the Privacy Policy